September 13, 2019Science ImmunologyOpen Access

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

View Full Paper

Ask AI

Bookmark

Abstract

T cell responses, and T follicular helper and germinal center B cell responses. The trivalent nucleoside-modified mRNA-LNP vaccine is a promising candidate for human trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Awasthi et al. (2019) studied this question.

synapsesocial.com/papers/6a45e41ac669e74762d0acde https://doi.org/10.1126/sciimmunol.aaw7083

View Full Paper

Ask AI

Bookmark

Abstract

T cell responses, and T follicular helper and germinal center B cell responses. The trivalent nucleoside-modified mRNA-LNP vaccine is a promising candidate for human trials.

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

Abstract

Discussion

Cite This Study

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

Abstract

Discussion

Cite This Study

Keep reading

Keep reading